for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Leap Therapeutics Inc

LPTX.O

Latest Trade

1.79USD

Change

0.00(0.00%)

Volume

315,644

Today's Range

1.75

 - 

1.90

52 Week Range

0.57

 - 

3.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Leap Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* LEAP THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text : (http://bit.ly/2I0IyH4) Further company coverage:

BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.65

* LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND ANNOUNCES DATE OF ITS ANNUAL MEETING OF STOCKHOLDERS

BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy

* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage:

BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders

* LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2jdjIfs) Further company coverage:

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

BRIEF-Leap Therapeutics announces $18 million private placement offering

* Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock

BRIEF-Leap Therapeutics qtrly loss per share $0.73

* Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial

BRIEF-Leap Therapeutics announces collaboration with EORTC

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

BRIEF-Leap Therapeutics says Q2 loss per share $0.74

* Q2 loss per share $0.74 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Leap Therapeutics Q2 net loss $6.9 mln vs $7.5 mln, a year earlier

* Leap therapeutics reports second quarter 2017 financial results

BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study

* Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg)

BRIEF-Leap Therapeutics announces collaboration with Merck

* Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up